WeedVoice

An online media news aggregator and blog for the cannabis and hemp industry world-wide.

MJS News & Trends- January 19, 2018

This Year’s Top 3 Canadian Marijuana Stocks

This year is a HUGE year for Canada, as our neighbor to the north will legalize adult-use recreational marijuana this upcoming summer. Over the last trailing year, marijuana stocks have grown tremendously, and investors cannot wait to see what this year has in store with the addition of a new market. Investors remain bullish on the industry since there really isn’t much to put out the fire of these hot marijuana stocks. Here are my top 3 picks in terms of Canadian marijuana stocks that you should consider adding to your portfolio this year.

Read More.

It’s Official, Pennsylvania’s First MMA Dispensary Has Opened!

After months of waiting, Pennsylvania’s first ever medical marijuana dispensary has opened in the Lehigh Valley area. Keystone Canna Remedies is in the small town of Bethlehem, PA and now is officially permitted to begin selling medicinal marijuana to eligible patients who possess medical cards.

Full Story.

Houses Located By Recreational Marijuana Shops Increase in Value

Researchers looking at the result of legalized recreational marijuana on Denver’s home prices found a shocking trend: marijuana shops that began selling recreational cannabis had a “large positive impact on neighboring property values.”

Continue reading
0 Comments

This Year’s Top 3 Canadian Marijuana Stocks

This year is a HUGE year for Canada, as our neighbor to the north will legalize adult-use recreational marijuana this upcoming summer. Over the last trailing year, marijuana stocks have grown tremendously, and investors cannot wait to see what this year has in store with the addition of a new market. Investors remain bullish on the industry since there really isn’t much to put out the fire of these hot marijuana stocks. Here are my top 3 picks in terms of Canadian marijuana stocks that you should consider adding to your portfolio this year.

3. MedReleaf Corp. (MEDFF)

MedReleaf, although the smallest of the Canada’s four key players at $2.24 billion, has been consider one of the most undervalued marijuana plays. This marijuana stock has major potential, here’s why.

The federally licensed producer has acquired a large following from great satisfaction achieved from its premium-quality products from its customers. Although cannabidiol is not legal just yet, MedReleaf has already been recognized by the Lift Awards, taking home the titles for “Top High-CBD,” “Top Sativa,” and “Top Indica” over the past few years.

This marijuana stock prides itself on being a producer of premium medical-grade marijuana. MedReleaf is not only the first but the only ISO 9001 certified marijuana producer making the company good play for investors seeking a “pharma-like” play. MedReleaf is scheduled to reinvest a great deal back into research and development for further product enhancement.

Continue reading
0 Comments

It’s Official, Pennsylvania’s First MMA Dispensary Has Opened!

After months of waiting, Pennsylvania’s first ever medical marijuana dispensary has opened in the Lehigh Valley area. Keystone Canna Remedies is in the small town of Bethlehem, PA and now is officially permitted to begin selling medicinal marijuana to eligible patients who possess medical cards.

“Welcome to the 21st Century,” said Tony Iannelli, CEO and president of the Greater Lehigh Valley Chamber of Commerce following the dispensary’s grand opening.

However, the dispensary, although technically open. will not begin selling medicals until February. It is presently open to the public for consultations as well as educational workshops for the meantime. When the dispensary does begin retailing products, consumers will have a variety to choose from.

Due to Pennsylvania’s state laws, flowers and edibles will not be available for purchase. However, consumers will be able to choose from many other options such asvaporizers, oil cartridges, tinctures and even lotions. Customers will also be able to customize their orders to echo their personal preferences by choosing products that contain strictly THC, CBD, or both.

Victor Guadagnino Jr., founder of the dispensary along with his father, Dr. Victor Guadagnino, and aunt, Joan Guadagnino, praised how the state of Pennsylvania and Governor Tom Wolf have handled the initiation of a medical marijuana program in the state. It was also added that Wolf’s open-minded mentality regarding medical marijuana is a key part as to why they chose Pennsylvania as the foundation of their business.

Continue reading
0 Comments

Houses Located By Recreational Marijuana Shops Increase in Value

As recreational marijuana sales begin to spike throughout California’s Bay Area, could the recently legal crop end up creating an unexpected type of boom — in the real estate market?

Researchers looking at the result of legalized recreational marijuana on Denver’s home prices found a shocking trend: marijuana shops that began selling recreational cannabis had a “large positive impact on neighboring property values.”

After recreational sales became legal, houses close to a participating marijuana shop noticed their value increase more than 8 percent relative to homes located slightly farther away, the study found. It’s a small study based on data from only one metro area, but the research — the first of its kind — could provide an important glimpse into the potential impact of legalization.

“We went into the project and we weren’t really sure what to expect,” said James Conklin a real estate professor at the University of Georgia who co-authored the paper called “Contact High: The External Effects of Retail Marijuana Establishments on House Prices” last summer. “We thought maybe there would be a negative impact. I think our takeaway after working on the project was that we don’t see a negative effect — we do see results point to a positive effect.”

Conklin and his co-authors found that after recreational marijuana sales became legal in Denver at the beginning of 2014, single-family homes positioned near dispensaries saw their values go up. Homes within 0.1 miles of a dispensary saw gains of 8.4 percent relative to houses located between 0.1 and 0.25 miles away.

Continue reading
0 Comments

MJS Midmorning Update- January 18, 2018

Vitality Biopharma, Inc. (VBIO) Submits Orphan Drug Designation Request to FDA

Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). Read More.

A Royalty Marijuana Stock?

Canada’s marijuana stocks continue to grow at a rapid pace. Medical marijuana has been legal since 2001, and the country’s Health Canada had reported in May that the number of eligible medical marijuana patients was increasing by 10 percent each month. With Canada on track to open an additional stream of revenue from the legalization of recreational marijuana this July, no wonder investors are loading up on positions in marijuana stocks. Click Here For More.

Maryland Credit Union Offering Banking Services For Marijuana Companies

Although the marijuana industry continues to bud at a rapid pace, there is one thing that prevents most marijuana companies to progress as fast as they would like. A reliable banking service. Unfortunately, since marijuana remains illegal at the federal level and is classified as a Schedule 1 narcotic, most financial institutions are weary to get into business with marijuana companies. But, in Maryland, a credit union is offering banking services for marijuana businesses. Full Story.

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Continue reading
0 Comments

A Royalty Marijuana Stock?

Canada’s marijuana stocks continue to grow at a rapid pace. Medical marijuana has been legal since 2001, and the country’s Health Canada had reported in May that the number of eligible medical marijuana patients was increasing by 10 percent each month. With Canada on track to open an additional stream of revenue from the legalization of recreational marijuana this July, no wonder investors are loading up on positions in marijuana stocks. Although most Canadian marijuana stocks have skyrocket over the past year, most are losing money annually due to a large amount of spending to expand their capacity.

This can change. A somewhat new player has joined the green rush of the marijuana industry, Cannabis Wheaton Income Corp. (CBWTF). This is the world’s first publicly traded royalty marijuana stock, yes, you read that right. The company may sound familiar to you because the company was named and structured after precious-metal streaming company Wheaton Precious Metals (WPM) whose headquarters can be found in our neighbor to the north.

The idea is not only simple but genius. A marijuana streaming company can help marijuana companies that are seeking expansion of their grow capacity or any other operations related expansion as these companies, more often than not, do not have the funding to do so. That is where Cannabis Wheaton (CBWTF) comes in. In exchange for capital, Cannabis Wheaton (CBWTF) would receive a royalty percentage of the company, just as WPM.

The company stated that there are no recurring costs nor any daily maintenance expenditures for a streaming company. It is as simple as making deals and generating high-margin returns from the sales of the stream at current market prices. According to the company, it has an internal rate of return of over 60% on its deals, not too shabby.

Let’s do the math. Cannabis Wheaton (CBWTF) can achieve the rate through an estimated cost of goods sold per gram of $2.50 Canadian, roughly $2.01 U.S. dollars. Relatively, the average selling price per gram of Canadian marijuana CA$7.75 or $6.22 U.S. dollars. That equates to an EBITDA (earnings before interest, taxes, depreciation, and amortization) per gram sold of CA$5.25 or $4.21 U.S.

Continue reading
0 Comments

Maryland Credit Union Offering Banking Services For Marijuana Companies

Although the marijuana industry continues to bud at a rapid pace, there is one thing that prevents most marijuana companies to progress as fast as they would like. A reliable banking service. Unfortunately, since marijuana remains illegal at the federal level and is classified as a Schedule 1 narcotic, most financial institutions are weary to get into business with marijuana companies. But, in Maryland, a credit union is offering banking services for marijuana businesses.

The Bulldog Federal Credit Union has begun to offer banking services to meet the needs of Maryland’s up and coming medical marijuana industry. The services began just this year, and according to BFCU President David Barrett, the efforts serve the MMJ community’s most vital need.

“It’s a perfect fit,” said Barrett in a press release. “As a financial institution, we recognize the need for medical cannabis entrepreneurs to be able to conduct a business in a forthright, transparent and compliant manner that is both safe and part of the state regulatory environment.”

Despite the federal government’s ancient option of marijuana legalization, including the latest behaviors of Attorney General Jeff Sessions, the BFCU has succeeded in creating a not only a safe and reliable but legal way for marijuana businesses to store their funds. Barrett also is confident that his system will take away from the black market and in time create a safer community.

“By offering our services to the cannabis industry, we will help remove large sums of cash from our streets, making the environment safer for our communities, friends and most importantly, our families,” said Barrett. “By providing safe, compliant, economical financial solutions to the entrepreneurs in Maryland’s medical cannabis industry, we hope to help them to realize growth and prosperity legitimately, and that will benefit not only our members but our community at large and our local economy.”

Continue reading
0 Comments

American Cannabis Company, Inc. (AMMJ) Announces It Has Secured A Contract With A New Client In California

American Cannabis Company, Inc. Announces It Has Secured A Contract With A New Client In CaliforniaAmerican Cannabis Company, Inc. (AMMJ) (“ACC”), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced that it has secured a consulting contract with Cloud 9 Apothecary in the state of California. In conjunction with the consulting agreement, ACC will acquire an equity stake in Cloud 9’s project that is currently non-operational and in the development stage.

This project, to be built-out and completed in Desert Springs, California, will comprise a closed-loop greenhouse containing a 22,000 square foot canopy of premium cannabis cultivars. With the construction of this facility, Cloud 9 Apothecary’s plans focus on wholesale cultivation and product manufacturing. Plans to shift into a fully integrated business model, complete with dispensing solutions, will be made in the near future as Cloud 9 plans to scale up operations organically.

Remington Hudson, Cloud 9’s CEO commented: “Our mission is to be the apex provider of premium cannabis flower products in the state of California. All of our products are grown and developed to ensure that dispensaries consistently receive premium, healthy, organic cannabis products. We are committed to being the state’s leader in quality, compliance, innovation, cutting-edge equipment, and social responsibility. Strategic partnerships are something we believe will catapult Cloud 9 Apothecary into a statewide and national brand. These are a few of many reasons we partnered with American Cannabis Company; we are proud and confident that our partnership with ACC will be successful.”

Terry Buffalo, CEO of American Cannabis Company, commented: “ACC is very happy to have joined forces with Cloud 9 Apothecary as the California market continues to bloom. Our company will work to ensure that this client group has the tools that it needs to thrive in this competitive marketplace. In taking an equity position with Cloud 9, ACC aims to be a long-term service and solution provider in an effort to continually expand the footprint of their business model.”

About American Cannabis Company, Inc.

American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. American Cannabis Company also developed and owns a portfolio of branded products including: The Satchel™, SoHum Living Soils™, The Cultivation Cube™ and the High-Density Cultivation System™. We also design and provide other industry-specific custom product solutions. The building and development of our brands and product suite are based on our Geoponics Philosophy, “the art and science of agriculture in soil.”

Continue reading
0 Comments

MJS Trends – January 17, 2018

Sessions: Can’t Touch These Marijuana Stocks

Although Attorney General Jeff Sessions has begun his war against U.S. marijuana stocks, it doesn’t mean his wrath will ripple where he doesn’t have any authority. In other words, Sessions’ thoughts regarding marijuana are nothing more than that of a peasant’s in other countries. The outlook for marijuana stocks, including U.S. marijuana stocks, remains bullish and will probably be their best year yet.

Read More.

Colorado Proposes New Bill For Marijuana Tracking System

Since 2012, the state of Colorado has been benefiting from the legalization of marijuana. The state’s Chief Medical Officer has said that there haven’t been any significant issues that have stemmed from marijuana’s legalization. But, as the state’s marijuana industry continues to bud, something is still missing. A tracking system.

Full Article.

Will New York Be The Next State To Go Fully Legal?

New York has dropped behind the majority of other states with fully comprehensive medical marijuana programs and legal recreational marijuana use. However, the topic has finally been presented to the state assembly. Is New York about to legalize recreational marijuana? Back on January 11th, 26 people testified before a committee to discuss New York’s future pertaining to legalizing recreational marijuana.

Continue reading
0 Comments

Future Farm Technologies Inc. (FFRMF) Raises Over $2.5 Million Through Voluntary Warrant and Option Exercises

Future Farm Raises Over $2.5 Million Through Voluntary Warrant and Option ExercisesFuture Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQB: FFRMF) is pleased to announce that $2,553,092 has been raised to date through the voluntary conversion of both its $0.35 and $0.37 warrants and through the exercise of options.

The $0.35 per share warrants expired on January 11, 2018, however Shareholders may still convert their $0.37 per share warrants into Future Farm’s common stock until March 7, 2018.

Shareholders wishing to exercise their warrants are asked to contact the Company by following the instructions below:

Enquiries by email:

Belinda Tyldesley at 

Original Warrant Exercise Forms and payment by way of certified cheque or bank draft payable to “Future Farm Technologies Inc.” should be delivered to  #510-580 Hornby Street, Vancouver, BC V63 3B6 or by wire transfer in Canadian funds to Future Farm Technologies Inc.  Wire instructions will be provided upon request.

Continue reading
0 Comments

Vitality Biopharma, Inc. (VBIO) Submits Orphan Drug Designation Request to FDA

Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA).

Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease.  The U.S. Orphan Drug Act (ODA) of January 1983 is meant to encourage development of drugs for rare diseases, and review by the FDA’s Office of Orphan Products Development can expedite the evaluation and eventual market approval of products that demonstrate significant promise for the treatment of these conditions.

Vitality Biopharma’s gut-targeted cannabosides enable delivery of THC without psychoactivity or intoxication, which may enable more widespread use of cannabinoids for treatment of pediatric digestive disorders.  The Company has already completed studies that demonstrate the efficacy of cannabosides for treatment of preclinical models of colitis.  Cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls.

“In young children, ulcerative colitis can often be hyperactive and difficult to control using existing FDA-approved medications,” said Robert Brooke, CEO and Co-Founder of Vitality Biopharma. “Given the mounting clinical data documenting use of cannabinoids for treatment of gastrointestinal disorders, we are very excited about the potential of VITA-100 and our cannabosides platform to provide a meaningful impact for these patients, helping them to stabilize their disease and avoid debilitating surgeries.”

About Vitality Biopharma (VBIO)Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking StatementsThis news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Continue reading
0 Comments

Sessions: Can’t Touch These Marijuana Stocks

Although Attorney General Jeff Sessions has begun his war against U.S. marijuana stocks, it doesn’t mean his wrath will ripple where he doesn’t have any authority. In other words, Sessions’ thoughts regarding marijuana are nothing more than that of a peasant’s in other countries. The outlook for marijuana stocks, including U.S. marijuana stocks, remains bullish and will probably be their best year yet.

With Canada approaching national adult-use recreational legalization this year, I expect nothing more than for Canadian marijuana stocks to seriously bud, especially marijuana growers. My top picks for Canadian marijuana growers are Canopy Growth(TWMJF), MedReleaf (MEDFF), and last by not least Aurora Cannabis(ACBFF).

The Canadian medical marijuana market continues to grow at a rapid pace, Health Canada reported that the number of eligible medical marijuana patients continue to grow by 10 percent each month. The medical marijuana market is enough for these marijuana stocks to remain profitable. All three of these companies have also expanded into international markets to export their dried medical marijuana to markets that either cannot meet grow demands or do not have a domestic grow law in place just yet.

These marijuana stocks also have a high production capacity in hopes to meet the demands of the highly anticipated recreational market. Keep in mind this is an entirely new market for these companies to generate revenue. Canada’s new market is forecasted to generate anywhere between $4.2 billion and $8.7 billion annually.

The North American legal marijuana market grew 34 percent in 2016 to $6.9 billion, and is predicted to surpass $21.6 billion by 2021. This suggests a five-year compound annual growth rate of 26 percent. The marijuana industry’s rapid growth is what continues to attract investors. I think that we can look forward to significant growth in Canadian marijuana stocks this year with the anticipation of legalization as the industry continues to progress. I remain bullish on the industry in general and do not see it slowing down anytime soon, sorry Sessions.

Continue reading
0 Comments

Colorado Proposes New Bill For Marijuana Tracking System

Since 2012, the state of Colorado has been benefiting from the legalization of marijuana. The state’s Chief Medical Officer has said that there haven’t been any significant issues that have stemmed from marijuana’s legalization. But, as the state’s marijuana industry continues to bud, something is still missing. A tracking system.

Marijuana tracking system is far from an innovative idea, some marijuana businesses have been using this type of technology for years. But, in a new bill, the state has suggested to implement a method similar to this in the Senate Bill 18-029.

The bill requires the institute of cannabis research at Colorado state university to create a marijuana tracking technology. It is required that the technology will possess an agent that can be applied to a marijuana plant, marijuana product, industrial hemp, or industrial hemp product and then scanned by a device. The scan will ultimately determine if the product was grown, manufactured and distributed legally. Dispensary owners and law enforcement will be able to verify the exact source of a product with just one scan, sounds easy enough.

But, what about potential downsides? The Senate’s proposed bill calls for an unnamed “agent” to be applied directly to the product. This unspecified “agent” could be a sticker, microchip, a tag, the list can go on. But, for the most part, the products we will be scanning are actual plants.

For those who will be responsible for creating and manufacturing these marijuana tracking systems will need to keep in mind that whatever is applied to the products, specifically the plants, cannot disrupt neither the biological nor chemical components. If a marijuana tracking system alters a plant at a seed or even a cellular level, this opens the doors for a multitude of issues.

Continue reading
0 Comments

Namaste Technologies Inc. (NXTTF) Reaffirms Position on No US Exposure

Namaste Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA StatementNamaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (M5BQ.F), (NXTTF) would like to reaffirm its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions. Further to the Company’s Nov 28, 2017 press release, and in lieu of the recent rescission of the Cole Memorandum by US Attorney General Jeff Sessions, Namaste’s position on staying out of the US cannabis market remains firm. The Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments. Namaste is highly focused on the expansion of its Canadian operations through the launch of its online medical cannabis marketplace. Management will have no involvement in operations or investments in any illegal jurisdictions which present any risk to the Company and/or its shareholders.

On January 12, 2018, the Canadian Securities Administrators (“CSA”) issued a statement following the rescission, whereby the CSA gave notice that it would re-examine its disclosure-based policy in relation to Canadian cannabis companies with any US operations or investments. Namaste believes that the CSA’s statement is in-line with the Company’s position and short-term outlook on the cannabis market in the United States.

Namaste will continue to focus on expansion of its international operations in progressive, legal markets by leveraging its technology and existing databases of cannabis consumers in countries around the world. Namaste, through its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is developing an online marketplace for medical cannabis that will offer patients the largest variety of product sourced from domestic and international producers. The launch of Cannmart is significant to Namaste, as the Company intends to follow the same strategy in other legal markets where it has established a strong presence.

Management CommentarySean Dollinger, President and CEO of Namaste comments: “We’re very pleased to have divested our US assets and operations. Namaste will continue focusing its efforts on progressive, legal markets like Canada and emerging legal cannabis markets like Australia and will remain uninvolved with any US cannabis operations until there are major changes to US federal laws.”

About Namaste Technologies Inc. Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking InformationThis press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Continue reading
0 Comments

Marijuana Software Might Be Invading The Cannabis Industry

Currently, the marijuana industry is still a cash-only business system. It’s illegal to possess and/or sell marijuana in most states, and some banks are still wary about investing in cannabis companies even in states where medical and recreational use is legal. This means that debit and credit cards cannot be used to purchase medicinal marijuana, and handling this much cash puts a lot of dispensaries and their customers at risk.

So how are marijuana shops rising up to meet this challenge?

Using software specifically designed with the marijuana industry in mind is one way suppliers, manufacturers, dispensaries, and users are all protecting themselves and their businesses. But this is more than just social media. You can’t just post pictures of your strains on Instagram to advertise your product, and with federal regulation still plaguing the industry, new software developers are working to meet the demand for new kinds of confidential currency exchange and marketing.

What Kind of Software are We Talking about?

This past week, a discussion took place to go over the desperate move on Massroots part to embrace blockchain and improve the company’s overall growth. It’s also an attempt to improve the back-end experience for dispensaries and their customers. But with the impetus around cryptocurrency so volatile, only time will tell if this was a smart business move or not.

Continue reading
0 Comments

Will New York Be The Next State To Go Fully Legal?

New York has dropped behind the majority of other states with fully comprehensive medical marijuana programs and legal recreational marijuana use. However, the topic has finally been presented to the state assembly. Is New York about to legalize recreational marijuana? Back on January 11th, 26 people testified before a committee to discuss New York’s future pertaining to legalizing recreational marijuana.

Here were the most pertinent and compelling testimonies:

Dr. Julie Holland, MD

Dr. Julie Holland has been a practicing psychiatrist for over 2 decades. Nine of which as the attending physician of the psychiatric emergency room at New York’s Bellevue Hospital. To start her testimony in favor of legalization, she stated that all Americans take drugs on a daily basis to change their consciousness. Drugs such as “caffeine, nicotine, anti-anxiety meds, antidepressants, sleeping pills, pain medications, alcohol and even sugar”. She likened the sugar cycle of crash and cravings to a “muted imitation” of a cocaine high.

Dr. Holland certainly stressed that cigarettes and alcohol kill Americans at a massive rate, compared marijuana which is non-lethal. She also pointed out while cannabis is detected in urinalysis, more harmful synthetic cannabinoids such as Spice or K2 are not and are being used by active members of the military. Therefore, she says that “our current drug policy is irrational.”

Continue reading
0 Comments

Marijuana Stocks Top Articles- January 16, 2018

GT Biopharma Inc. (GTBP) Welcomes Geoffrey B. Davis To The Board of Directors

GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) today announced that Geoffrey B. Davis will join GT Biopharma’s Board of Directors effective immediately. Mr. Davis is the founding partner of Barker Davis, a law firm focused on Life Sciences transactions, and formerly a partner at Ropes & Gray, where he played a significant role in establishing the firm’s internationally recognized Life Sciences group.

Read More..

Would Federal Marijuana Legalization Boost The Economy?

Many have been wondering what the answer to the question is. With simple deductive reasoning, the answer is clearly yes. U.S. states that have legalized marijuana are generating some solid revenue from taxes and fees. There are other benefits to legalization besides just tax revenue generation that the states have seen, such as increased employment as well as increased incentives for private investments. If separate states are seeing their economy advance, why would the country want that on a federal level?

Full Story..

3 Ways To Invest In Marijuana Stocks in 2018

Last year was a great year for marijuana stocks, but 2018 is expected to blow last year’s numbers out of the water. The North American Marijuana Index, which tracks 39 leading marijuana stocks, gained over 90% in 2017. Investors cannot wait to see what this year has in store with the addition of California’s and Canada’s recreational markets. Here are three different ways you can invest in marijuana stocks this year.

Continue reading
0 Comments

Tetra Bio-Pharma Inc. (TBPMF) Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

According to Health Canada data1, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1. According to an Eight Capital analysis2, the cannabis oil market is expected to reach 1.5B$ in 2024.

The launch of this trial is the first step in Tetra’s plans to commercialize natural health products with its partners. The corporation will develop cannabis-based supplements for commercialization under the Natural Health Product regulations in Canada and in other countries where regulatory authorities have a recognized pathway for approval and commercialization of such products. The trial will eventually include formulations that will be registered as drugs under Health Canada’s TPD regulatory pathway. “Tetra Bio-Pharma Inc. seeks to become an important player in the retail market post legalization and this clinical trial is part of the sales and marketing strategy required to effectively penetrate the lucrative pharmacy and health stores retail markets,” states Bernard Fortier, CEO of Tetra.

Tetra’s vision is to develop an evidence-based approach, thereby allowing pharmacists to dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are still hesitant to support the use of these products because of the lack of data supporting its medical use. Dr. Guy Chamberland, Chief Science Officer, commented: “This trial is part of Tetra’s corporate strategy to develop the science required to commercialize safe and efficacious cannabis oil products post-legalization and to create innovative oral drug formulations for the development of medicines in the management of pain, anxiety and the treatment of cancer.”

In that respect, Tetra’s scientific team is supporting the strategy by initiating a phase 1 clinical trial to characterize the safe use of these cannabis oil medicines in humans. Tetra has worked with Altasciences Clinical Research for the preparation of the Clinical Trial Application (CTA) for the conduct of a double-blind phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple daily doses of cannabis (Delta-9-tetrahydrocannabinol/Cannabidiol) oil capsules administered to healthy human volunteers. Health Canada issued a No Objection Letter for the conduct of the phase I clinical trial on January 12nd, 2018. Altasciences Clinical Research will be initiating the clinical trial activities in the coming weeks. The cannabis oil is manufactured by Tetra’s partner, Aphria Inc.

Continue reading
0 Comments

Zoned Properties, Inc. (ZDPY) Engaged in Strategic Advisory & Sale Leaseback Discussions for Multiple Locations

Zoned Properties Engaged in Strategic Advisory & Sale Leaseback Discussions for Multiple Locations

Targeting Property Development Projects for Licensed Medical Marijuana in California, Colorado, Florida and Texas

Zoned Properties, Inc. (ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed medical marijuana industry, today announced that the Company is in discussions with a number of prospective clients to develop licensed medical marijuana facilities located in California, Colorado, Florida and Texas.

“Building on the legislative momentum of the past two years, at least 12 states are considering marijuana legalization in 2018,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties. “We’re uniquely positioned to play a critical role as the strategic advisor for development of future medical marijuana projects. Through our Strategic Advisory Services, we provide clients with comprehensive due diligence and organizational assessments for targeted development properties. Our extensive industry knowledge and track record of success enables us to identify risks and design roadmaps to ensure a project’s success. Leveraging our strategies in Arizona and Colorado to pursue select opportunities in other states, we’re engaging with prospective clients to establish a basis for future sale leaseback transactions.”

“The accelerating legislative changes and policy reforms will create the need for experienced advisors to help clients navigate the licensed medical marijuana industry,” concluded McLaren. “We are allocating our resources selectively to optimize opportunities to grow our portfolio.”

Zoned Properties’ Strategic Advisory Services provides clients with comprehensive due diligence and an organizational assessment for properties under consideration for development, as well as master planning, architectural design and construction management.

Continue reading
0 Comments

Canadian Marijuana Stocks Have Some New Competition

The legal marijuana market is one of the most rapid growing industries, with most marijuana stocks doubling or even tripling in value over the last trailing year. The outlook on the industry remains highly bullish. According to leading marijuana researcher ArcView, the North American legal marijuana market grew 34 percent in 2016 to $6.9 billion, and is predicted to surpass $21.6 billion over the next three years. This would represent a five-year compound annual growth rate (CAGR) of 26 percent, which is why investors continue to load up in this budding industry.

Canada’s marijuana market has been most impressive. Our neighbor to the north has a long-standing medical marijuana program having legalized it back in 2001. Health Canada has reported that the number of eligible medical marijuana patients grows about 10 percent monthly. There are four key players of the Canadian marijuana stocks that control most of the country’s market, they are Canopy Growth Corp. (TWMJF) Aurora Cannabis (ACBFF), MedReleaf (MEDFF) and Aphria (APHQF). Canada also has to look forward the addition generation of revenue from an entirely new market come this July when adult-use recreational legalization commences.

Canadian cultivators have also generated some of their revenue from exporting dried marijuana overseas to countries that have legalized medical marijuana and either do not have a domestic grow program in place or cannot meet consumer demands. Aphria (APHQF), Canopy Growth (TWMJF), and Aurora (ACBFF) have all lifted their top-line results by exporting their products abroad. But, watch out Canada, there is some new competition in town.

Currently, there are just three countries that are permitted to export dried marijuana abroad for medicinal purposes which are Canada, Uruguay, and the Netherlands. But, Australia has just announced its intention to export medical marijuana which resulted in shares of two Austrian marijuana cultivators AusCann Group (ACNNF) and Cann Group (CNGGF) skyrocketing.

With the global medial marijuana market valued at $55.8 billion, no wonder Australian growers are grinning from ear to ear. Although the current demand is being mostly met by Canada, there is still a large unmet need in several European countries. Both, Auscann (ACNNF) and Cann Group (CNGGF) would accept the opportunity to export excess production abroad to markets in need. The proposal still needs to be passed by federal parliament when it returns to session in February, with the Labor Party having already indicated its intention support the proposal.

Continue reading
0 Comments

GT Biopharma Inc. (GTBP) Welcomes Geoffrey B. Davis To The Board of Directors

Geoffrey B. Davis Joins GT Biopharma’s Board of Directors

GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) today announced that Geoffrey B. Davis will join GT Biopharma’s Board of Directors effective immediately. Mr. Davis is the founding partner of Barker Davis, a law firm focused on Life Sciences transactions, and formerly a partner at Ropes & Gray, where he played a significant role in establishing the firm’s internationally recognized Life Sciences group.

“As a veteran life sciences attorney, Geoff’s experience will complement the seasoned biotechnology management team that we added over the last 6 months. His appointment represents another milestone for GT Biopharma and significant accomplishment towards our goal of creating a premier company in the biotech community,” said Anthony J. Cataldo, Executive Chairman of GT Biopharma.

“We are extremely pleased to welcome Geoff to GT Biopharma’s Board of Directors,” said Dr. Kathleen Clarence-Smith, Chief Executive Officer of GT Biopharma. “We expect Geoff’s substantial experience and expertise, particularly in the completion of business development transactions, to be a significant asset to the company, as we continue to execute on our strategy, focused on becoming a leading biopharmaceutical company.”

Mr. Davis has extensive experience representing biotechnology, biomedical, medical device and pharmaceutical companies. During his more than 25 years as a partner at Ropes & Gray, Geoff played a significant role in establishing the firm’s internationally-recognized Life Sciences group. His work includes numerous corporate partnering and licensing transactions for major pharmaceutical and medical device companies, as well as for public and private biotechnology companies and major medical centers. He has also worked extensively on public and private financings for biomedical companies of all sizes, ranging from newly organized companies to established industry leaders, on behalf of both companies and their investment bankers.

Mr. Davis received his B.A., cum laude, from Yale University and his J.D., cum laude, from Harvard Law School.

Continue reading
0 Comments

Namaste Technologies Inc. (NXTTF) Announces Participation as Lead Order in Atlas Growers Private Placement

Namaste Announces Participation as Lead Order in Atlas Growers Private Placement and Secures 20% of Net ProductionNamaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (M5BQ.F), (NXTTF) is pleased to announce that the Company is participating as a lead order in a private placement offering (“Private Placement”) by Atlas Growers Ltd. (“Atlas”), which is a late-stage applicant for an Access to Cannabis for Medical Purposes (“ACMPR”) cultivation and sales license. In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) have entered in to a Supply Agreement (the “Supply Agreement”) whereby Atlas agrees to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas.

The Company’s participation in the Private Placement and subsequent Supply Agreement offer significant value to Namaste shareholders not only as an investment, but also in securing a reliable supply of high quality medical cannabis. The Company believes Atlas’ strong management team and business plan provide a strategic partnership opportunity with Atlas to ensure a guaranteed cannabis supply to Namaste, while at the same time broadening Atlas’ exposure to the market via Cannmart’s online retail channels. Namaste has completed the Subscription Agreement under the terms of the Private Placement, for C $200,000 in exchange for 200,000 Class B Common shares of Atlas stock at a price of C $1.00 per common share. The Supply Agreement will allow Cannmart to purchase bulk quantities of medical cannabis from Atlas based on the terms below.

Supply Agreement Terms

Atlas commits to Cannmart a first right of refusal to purchase up to 20% of Atlas’ productionThe term of the Supply Agreement is 24 monthsPurchase orders are to be submitted at least 14 days in advance of requested delivery datePayment terms are 30 days from delivery of a purchase orderCannmart will be responsible for delivery chargesThe Supply Agreement is subject to both companies receiving their ACMPR licenses.

Namaste will continue to explore additional opportunities for investments in domestic and international medical cannabis producers as it sees great value in securing equity and building a strong and reliable supply chain for Cannmart’s patients. Namaste plans to leverage its vast e-commerce expertise and technology, along with its existing consumer databases and site traffic, to create the largest online marketplace for medical cannabis in Canada. This strategic investment in Atlas clearly defines the Company’s strategy in developing strong supply relationships to achieve its goals. The Canadian market offers some unique opportunities as it relates to craft and/or boutique producers, and Namaste believes this niche will add significant value to its platform.   Canada has a long history of producing some of the highest quality and most sought-after cannabis in the world, and it is Namaste’s intention to ensure all producers have access to its distribution channels. Namaste expects to see a growing demand for the cannabis produced in these markets, much like that seen in the craft beer and wine industry. This partnership demonstrates the Company’s intention to leverage a broad range of supply chains, in an attempt to meet the wants and needs of our patients.

Management CommentarySean Dollinger, President and CEO of Namaste comments: “We’re very excited to be participating in this opportunity with Atlas and their team. We believe that Atlas will be an amazing strategic partner for Namaste in its ability to guarantee a reliable supply of cannabis for Cannmart. We are looking forward to working with Atlas to provide value and exposure for their brand. Namaste will continue to seek opportunities for partnerships with large and small ACMPR producers and will also focus on growing our vendor database to include premium craft cannabis brands. The opportunity to participate in this private placement brings value to the company as an investment but also in implementation of our strategy to become the most diversified marketplace for medical cannabis.”

Sheldon Croome, President and CEO of Atlas comments: “Our team is pleased to work with Namaste by providing our array of high quality cannabis products to their customers. In partnering with Namaste, both companies gain a significant strategic advantage as the market moves towards recreational legalization in 2018, and as the medical cannabis market expands. Namaste will be instrumental in bringing Atlas’ products to Eastern Canadian customers with the fastest possible delivery times, which we feel to be of excellent value to the end consumer. We are excited to bring additional value to Namaste and look forward to a strong, long term partnership.”

Continue reading
0 Comments

Aurora Cannabis Inc. (ACBFF) Completes Cornerstone Investment in The Green Organic Dutchman

Aurora Cannabis Completes Cornerstone Investment in The Green Organic DutchmanAurora Cannabis Inc. (“Aurora”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) and The Green Organic Dutchman Holdings Ltd. (“TGOD”) (privately held) today announced that the companies have completed Aurora’s strategic investment in TGOD, as previously announced on January 5, 2018 .

Pursuant to the terms of the agreement, Aurora has subscribed for subscription receipts through a private placement (the “Placement”), which shall automatically convert into units upon TGOD’s common shares being listed on a stock exchange in Canada (the “Listing Date”). Upon conversion, the units will provide Aurora with a 17.62% interest in TGOD on a non-diluted basis. As previously announced, the Placement consists of 33,333,334 units, priced at $1.65 per unit, for gross proceeds of $55 million . Each unit consists of one common share and one half of one common share purchase warrant, exercisable at $3.00 per common share for a period of 36 months following closing of the offering.

TGOD intends to complete an initial public offering in March of 2018, is currently completing the expansion of its Ancaster, Ontario facility and, together with Aurora Larssen Projects Ltd. (“ALPS”) has commenced the project to construct an 820,000 square foot high technology hybrid greenhouse facility in Valleyfield, Quebec , with a projected production capacity in excess of 100,000 kg of organic cannabis per annum.

Additionally, the parties entered into an investor rights agreement (the “Investor Rights Agreement”), whereby Aurora has the option to incrementally increase its ownership interest in TGOD to over 50% upon TGOD achieving certain operational milestones, as previously set out in the companies’ news release dated January 5, 2018 . The Investor Rights Agreement also provides Aurora with the right to participate in any new equity offerings of TGOD to maintain its pro rata ownership.

Supply Contract

The companies have entered into a supply contract, providing Aurora with the right to purchase up to 20% of the annual production of organic cannabis from TGOD’s Ancaster and Valleyfield facilities. This additional supply of more than 23,000 kg per annum will expand Aurora’s global funded annual production capacity to approximately 200,000 kg. Under the terms of the contract, Aurora can increase its offtake from these two facilities to 33% upon increasing its ownership interest in TGOD to 31%.

Continue reading
0 Comments

Would Federal Marijuana Legalization Boost The Economy?

Many have been wondering what the answer to the question is. With simple deductive reasoning, the answer is clearly yes. U.S. states that have legalized marijuana are generating some solid revenue from taxes and fees. There are other benefits to legalization besides just tax revenue generation that the states have seen, such as increased employment as well as increased incentives for private investments. If separate states are seeing their economy advance, why would the country want that on a federal level?

There are many studies that have focused on the impact of the legalization of marijuana to their economy, but there are not many studies that concentrate of the potential economic impact of federal legalization. Most of the economic gains that are discussed at the federal level are seen as what the government could eliminate. Basically, it’s about what the government could save, rather than gain.

The grueling and enduring War on Drugs continue to dig deep into the pockets of the federal government. The U.S spends more than $50 billion, according to the Drug Policy Alliance, each year to enforce its drug laws and imprison drug offenders, with little progress to stop the flow of drugs or reduce drug use throughout the nation.

A new study conducted by New Frontier Data, a research and marketing firm, is looking at what the country stands to gain The study concluded that the federal government would do pretty well if marijuana was taxed as a legal product. New Frontier CEO Giadha Aguirre De Carcer explained, “The three most common business taxes that any standard business pays to the federal government are federal business taxes, payroll taxes and sales tax”.

The study revealed that by combining those three tax bases, the government could generate an estimated $131.8 billion in revenue by 2025. Here’s how.

Continue reading
0 Comments

Friday’s Must See Marijuana Stocks News & Alerts – 1/12/2018

An *UPDATED* Recipe for Success & Longevity – Check This Out! Click HereLifestyle Delivery Systems Inc. (LDSYF) Announces Completion of Non-Brokered Private Placement Financing – Full News HereGT Biopharma Inc. (GTBP) Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004 – Full News Here

 

The post Friday’s Must See Marijuana Stocks News & Alerts – 1/12/2018 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Original link
0 Comments

Lifestyle Delivery Systems Inc. (LDSYF) Announces Completion of Non-Brokered Private Placement Financing

Lifestyle Delivery Systems Announces Completion of Non-Brokered Private Placement Financing and Grant of Stock OptionsLifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF) (FSE: LD6) (WKN: A14XHT) (“LDS” or the “Company”) is pleased to announce that it has closed a non-brokered private placement financing (the “Financing”) of a total of 5,500,000 units (the “Units”) at a price of Cdn$0.50 per Unit (the “Issue Price”), for total gross proceeds of Cdn$2,750,000. Due to strong investor demand, the Financing was oversubscribed.

Each Unit sold in the Financing consisted of one common share of the Company (each a “Unit Share”) and one common share purchase warrant (each a “Warrant”) entitling the holder to purchase one additional common share (a “Warrant Share”) at a price of $0.75 per Warrant Share for a period ending one year from the date of issuance. The Company may accelerate the expiration date of the Warrants if the daily volume weighted average share price of the Company’s common shares on the Canadian Securities Exchange (or such other stock exchange as the Company’s common shares are then trading on) is equal to or greater than Cdn$1.50 for 10 consecutive trading days.

The securities issued under the Offering will be subject to a hold period expiring on May 12, 2018, pursuant to applicable Canadian securities laws.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of any of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

Grant of Stock Options

On January 11, 2018, the Company granted an option to acquire up to 500,000 stock options to Mr. Arni Johannson, the Company’s consultant and management’s nominee for a director position at the upcoming Annual General Meeting to be held on January 25, 2018. The option is exercisable into common shares of the Company at an exercise price of Cdn$1.15 per common share and expire on a two-year anniversary of the grant.

Continue reading
0 Comments

3 Ways To Invest In Marijuana Stocks in 2018

Last year was a great year for marijuana stocks, but 2018 is expected to blow last year’s numbers out of the water. The North American Marijuana Index, which tracks 39 leading marijuana stocks, gained over 90% in 2017. Investors cannot wait to see what this year has in store with the addition of California’s and Canada’s recreational markets. Here are three different ways you can invest in marijuana stocks this year.

The first and most obvious way is to invest in marijuana stocks would be marijuana producers. In my opinion, currently, the best opportunities for marijuana producers are out of our neighbor to the north, Canada. There are a few reasons why I have come to this conclusion. Canada has had a long-standing medical marijuana program which is currently budding. Health Canada has reported that medical marijuana patients continue to grow by 10 percent each month. The country is on the verge of national recreational legalization which is going to open a whole new market forecasted to generate between $4.2 billion and $8.7 billion annually. There has also been some serious deal-making among Canadian marijuana companies and they are getting the attention of the mainstream media.

Canopy Growth (TWMJF) is in a great position to capture a large share of the recreational market. Right now, Canopy is the kingpin of all marijuana stocks by market cap and is the largest provider of Canadian medical marijuana. The history-making deal with Fortune 500 alcoholic beverage maker Constellation Brands (STZ) also puts this marijuana stock in position to continue its growth during 2018.

Another Canadian grower I’m bullish on is Aurora Cannabis (ACBFF) The company is in the middle of a hostile takeover attempt of CanniMed Therapeutics (CMDFF). If this deal comes into fruition, Aurora gains significantly greater production capacity which puts the company in a better position to stanch a larger portion of Canada’s recreational marijuana market.

Marijuana cultivators aren’t the only way to invest in marijuana stocks. There are multiple biotech companies that concentrate on developing and marketing cannabinoid drugs. As the thought of utilizing some form of marijuana becomes more accepted globally and there is increased research on the benefits in treating a multitude of ailments with cannabinoids, this is a great space for investors to get into the market.

Continue reading
0 Comments

Vermont Senate Legalizes Recreational Marijuana

There has been a lot of speculation on which state would be the next to legalize marijuana. Although Vermont already has a medical marijuana program in place, Governor Phil Scott had vetoed a bill that would legalize it just last May. Even though he vetoed the bill, the idea of legalization did not disappear. Governor Scott wanted to settle each detail prior to progressing with the bill.

And now, the state Senate of Vermont has passed a bill that legalizes recreational marijuana. What is more fascinating is that this move was not done by a ballot measure, but rather solely through the state legislature.

This time around, Governor Scott is likely to sign this bill into law. The bill is like that of other states’ legalization regulations. Individuals over the age of 21 will be permitted to possess up to one ounce of marijuana and can cultivate two plants at a time. But, there have not been any transparent plans released regarding retail.

Although the preliminary regulations follow suit to those of other states with legalized marijuana, the way in which the bill was passed is unquestionably different. They passed the bill through a legislative vote rather than through a public ballot. Maybe this doesn’t seem like a huge deal, but it sure is.

What a legislative vote means is that the state’s lawmakers publicly announced themselves to be pro-legalization. There was no hiding of their opinions behind the mask of public voting which carries a measure of risk especially with a topic as controversial as marijuana. Especially since recently, Attorney General Jeff Sessions rescinded the Cole Memo, which prohibited federal law enforcement from interfering with states with legal marijuana.

Continue reading
0 Comments

Reliq Health Technologies Inc. (RQHTF) Reaches over 6,000 Patients Live on Its iUGO Care Platform

Reliq Health Technologies Reaches over 6,000 Patients Live on Its iUGO Care Platform, and Announces that the Company has Achieved ProfitabilityReliq Health Technologies Inc. (RHT.V) (RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) solutions for Community-Based Healthcare, is pleased to announce that it closed 2017 with over 6,000 paid subscribers using its iUGO Care chronic care management, remote patient monitoring and telemedicine platform, representing recurring monthly revenue of over US$300,000/month. As a result, December 2017 was the Company’s first month of profitability.

“We are excited to announce that we now have over 6,000 patients live on our iUGO Care platform,” said Dr. Lisa Crossley, CEO of Reliq Health.  “The onboarding of patients is starting to accelerate as we move forward with our roll out to over 40,000 patients with the three current contracts in Texas.  We are also very pleased to announce that we have achieved another critical milestone, as the Company reached profitability in December 2017.  We continue to focus our efforts on the front line care providers in the US who are serving the over 37 Million Medicare and Medicaid patients who have two or more chronic diseases such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD) and congestive heart failure.  This market will continue to grow as the population ages and expands, and as pressure from lawmakers and insurers to reduce healthcare spending increases.  Our iUGO Care platform allows healthcare providers to proactively manage complex chronic care patients in the lower cost community setting, reducing the need for costly acute interventions such as hospital stays, surgeries, long term care admissions and ER visits.”

Reliq’s iUGO Care digital health solution provides high quality virtual care in the community by creating a “virtual hospital ward” within the patient’s home, automatically collecting vital signs and encouraging and tracking medication adherence. iUGO Care’s unique interactive voice technology provides patients with audible alerts and reminders to take their medications, collect their vitals using Bluetooth-enabled monitoring devices and perform prescribed rehab or fitness activities.  iUGO Care’s two-way voice hub provides voice-activated access to patient education content, empowering patients and family members to proactively manage complex chronic conditions.  Reliq’s iUGO Care cloud platform instantly alerts the clinical care team if a patient develops key warning signs, allowing clinicians to intervene before a health crisis occurs, preventing costly and disruptive hospital readmissions and ER visits.

ON BEHALF OF THE BOARD

“Dr. Lisa Crossley”

CEO and Director

Continue reading
0 Comments

Thursday’s Top Stories- January 11, 2018

California: Billions Up For Grabs

Surprisingly, few analysists have done deep dives into one of the largest cannabis marketplaces in the world, California. Reasons for the lack of investment advice may include the uncertainty regarding the multitude of rules, regulations and laws at all levels of government; from municipalities, to counties, to the State level. However, the investor that comprehends the approach of, “this too shall pass” to to their investing could be well prepared for the cannabis industry.

Read More..

Maine Lawmaker Wants To Give Children Access To Medical Marijuana

Although America is warming up to the idea of marijuana legalization with 64% believing its use should be made legal, according to a Gallup poll, but this view is for mainly for adults. Some states have made strides by permitting access to children with certain ailments, yet doctors still feel uneasy about prescribing pot to minors. There is one state that is fighting to give children more access to the benefits of medical

Full Story, Here..

A Recipe for Success & Longevity

We at Marijuana Stocks have been covering GT Biopharma, Inc OTCQB: (GTBP)(previously Oxis International) for almost 3 years. (GTBP) by far has been the longest running company we have provided coverage to & for GREAT REASON. (GTBP) is constantly evolving, becoming the best version of itself. (GTBP) has consistently provided our members with double & even triple digit short term and long-term gains.

Continue reading
0 Comments

American Green, Inc., (ERBB) Establishes Canadian Partner for Distribution of Its AGM for Verified Vending

American Green Establishes Canadian Partner for Distribution of Its AGM for Verified VendingAmerican Green, Inc., (OTC PINK: ERBB) is proud to announce that an agreement has been signed with Dispension Industries Incorporated (http://dispension.ca) to be its exclusive Canadian distributor. American Green has revolutionized the safe and secure management of regulated products, including cannabis products and pharmaceuticals, with its new generation of its AGM, branded the Verified Identity Dispenser in Canada. The first machines to arrive in Canada are earmarked for viewing and demonstration to the public, private sector, and key stakeholders in Halifax, Nova Scotia.

The Verified Identity Dispensers will play a vital role in the distribution of cannabis products as pot legalization looms in Canada.  While Canada is embracing the Green Rush, the country also recognizes the need for safe and secure distribution of these products. Prior to machine access, registered users are verified by scanning their finger using industry leading vascular biometric technology.

“To comply with pending Canadian cannabis regulations and the requirements set forth by our government there is only one system that we feel can meet and exceed their objectives, and that is the VID”, said Corey Yantha, president of Dispension Industries.

“American Green, and specifically the vending expertise and knowledge that Lindel Creed (Director of Automated Machine Production) contributes, has allowed our business model to operate in a streamlined, and efficient manner. We look forward to a long, and prosperous relationship with American Green”, Mr. Yantha concluded.

“Making a decision to award a nationwide distributorship is not something to take lightly of course”, commented American Green’s Lindel Creed. “With three decades in the industry I have seen successes and failures, very often dictated by the type of distribution partners you have. After several months of discussions and working with Corey and his team at Dispension Industries, I’m sure we have the right partner for Canada”.

“We have been confident in this market segment for nearly ten years. It was only a matter of time before the demand found its way to us and the AGM [the Verified Identity Dispenser or VID in Canada]” added David Gwyther, President and Chairman at American Green. “Our challenge will be keeping up with demand now that the market has arrived, and between our own team and our partners in the business, we have no doubt we can do that. These are exciting times”, finished Gwyther.

Continue reading
0 Comments

Future Farm Technologies Inc. (FFRMF) Signs LOI to Acquire Controlling Interest in Massachusetts Dispensary and Grow Operation

Future Farm Signs LOI to Acquire Controlling Interest in Massachusetts Dispensary and Grow Operation

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE:FFT) (FFT.CN) (FFRMF) is pleased to announce that it has signed a LOI to acquire a 51% interest in Bristol County Wellness Center, Inc. (“BCWC”). BCWC was recently awarded a special permit from the City of Attleboro and a provisional license from the Department of Public Health to build and operate a 24,700-sq ft. Registered Marijuana Dispensary (“RMD”) that will grow and sell medical marijuana, plus two additional dispensaries upon approval. This vertically integrated license allows BCWC to build out its facility and engage in cannabis cultivation, processing and retailing.

William Gildea, CEO of Future Farm comments, “We are pleased to be working with the experienced team at BCWC, and thrilled about the potential to operate in Massachusettssince it further positions our Company for revenue growth in 2018.” He continues, “This transaction allows us to operate in a state that has approved, but not yet implemented, the recreational use of cannabis, which positions us as one of the first movers in the state.” In Massachusetts, licensed RMDs applying for an adult use license will be given prioritized application review by the state.

The timetable calls for construction to begin in the next thirty days, and revenue to begin in the third quarter of 2018. BCWC is provisionally licensed to cultivate cannabis with up to 300 lights, process and extract oil to make edibles, and sell through a medical dispensary. BCWC may also sell up to 30% of its cannabis to other dispensaries. ArcView Market Research & New Frontier Research estimates the adult use recreational market in Massachusetts to be $1.17 billion by 2020.

Derek Ross, BCWC’s spokesman comments, “Unlike other states, such as Colorado, Washington or California where adult cannabis use is legal, Massachusetts is located within driving distance to many of the most densely populated states in the US. We anticipate that our facility, which will be conveniently located 1.5-miles from Exit 1 on I-95, will contribute to an increase in Massachusetts’ cannabis tourism industry, providing state revenue, tax dollars, and job growth.”

As consideration for its 51% stake in the business, Future Farm agrees to pay BCWC $6,375,000, with $5 million in cash being allocated to build out the RMD. The remaining $1,375,000 is in the form of a non-interest bearing convertible note, repayable within 12-months or convertible into Future Farm’s common stock at a fixed price determined as of the closing price on January 10, 2018 (the “Note”). If the Note is converted, Future Farm anticipates issuing 1,117,886 shares of its common stock to BCWC.

Continue reading
0 Comments

Namaste Technologies Inc. (NXTTF) and Phivida Announce Exclusive Supply Agreement

Namaste and Phivida Announce Exclusive Supply AgreementNamaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (M5BQ.F), (NXTTF) is pleased to announce that it has signed a Global Digital Reseller-Supply Agreement (the “Agreement”) with Phivida Holdings Inc. (“Phivida”) (CSE:VIDA), (PHVAF).

As key terms in the agreement, Namaste has been approved as the preferred global online retailer and digital affiliate marketing partner for Phivida’s product line of premium hemp-derived Cannabidiol (“CBD”) infused functional beverages and clinical health products. The agreement includes a global online territory, targeting the launch in Germany and Australia (the “Territories”).

Phivida CBD beverages, extracts, juices and shots are professionally formulated by health care practitioners, made with premium ingredients, tested for quality, safety and manufactured to GMP standards. This Agreement represents a strategic initiative between both companies to promote high quality CBD products through Namaste’s platform and to the Company’s existing databases of users within the Territories. CBD is a cannabinoid compound which can be derived from both cannabis and hemp plants and plays a vital role in the emerging global medical cannabis market.

With Phivida’s management team having a strong background from the beverage industry and branding, including former senior executives from Redbull, Proctor and Gamble and McKesson’s, Namaste is pleased to be able to offer Phivida’s premium CBD beverages and infusions to its patients and practitioners globally, with an initial launch in Australia and Germany.

Terms of the Agreement

Namaste has exclusive rights for online retail of Phivida’s products in the TerritoriesThe Agreement is valid for a 24-month periodThe Agreement payment terms are net 30 daysNamaste shall be responsible for delivery costsNamaste will under no circumstance retail PHIVIDA products for a price that is less than the regular retail price at which the products are advertised on PHIVIDA’s websiteThe Agreement states that all online product marketing expenses within the Territories will be shared equally between PHIVIDA and NamasteThe Agreement is subject to obtaining a legal opinion from a designated legal firm, agreed to by both parties

Namaste’s globally diversified network of e-commerce sites and distribution centers will allow Namaste, in its partnership with Phivida, to reach users in new and emerging medical cannabinoid based medical and consumer health markets. This Agreement further represents Namaste’s commitment to deploy its strategic initiatives in an effort to bring the most innovative products to market. Namaste’s growing global database of consumers continues to provide value to the Company and its partners, as it aims to leverage its technical expertise relating to its cutting-edge SEO and machine learning technologies.

Continue reading
0 Comments

California: Billions Up For Grabs

Surprisingly, few analysists have done deep dives into one of the largest cannabis marketplaces in the world, California. Reasons for the lack of investment advice may include the uncertainty regarding the multitude of rules, regulations and laws at all levels of government; from municipalities, to counties, to the State level.

However, the investor that comprehends the approach of, “this too shall pass” to to their investing could be well prepared for the cannabis industry. The reason is that over time a coherent state-run system will be created that will unify the various regulations and bring certainty to the marketplace. The cannabis companies that withstand the test of time negotiating the barrage of challenges will be rewarded.

Fundamentals: Candidly speaking, it’s far too early to be concerned with fundamentals. Companies that have the potential to reach the billion-dollar valuation mark are probably going to have to postpone profit for growth in the next few years. The reason is simple: the industry is in its infancy. Organizations should be concentrating on gaining a larger footprint than delivering a bottom line. However, if on the rare occasion a California PubCo at this early stage demonstrates strong fundamentals, then you should seriously consider it as an option for your portfolio.

Management: Last month another California publicly traded company in the cannabis sector basically imploded due to poor management. We’re seeing this happen regularly. The idea of this particular company was valid, but the execution was not, in our opinion.

One of the key requirements in the public cannabis space is having significant management experience. This includes experience in the cannabis sector, knowing how to get your product to market, and identifying and rewarding loyalty within your team.

Continue reading
0 Comments

Maine Lawmaker Wants To Give Children Access To Medical Marijuana

Although America is warming up to the idea of marijuana legalization with 64% believing its use should be made legal, according to a Gallup poll, but this view is for mainly for adults. Some states have made strides by permitting access to children with certain ailments, yet doctors still feel uneasy about prescribing pot to minors. There is one state that is fighting to give children more access to the benefits of medical marijuana.

The Associated Press has reported that Republican politician Deborah Sanderson has put forth a bill that would grant Maine’s children access to medical marijuana. The bill allows children to be prescribed medical marijuana as well as access to even obtain it from medical providers on school property. The bill is scheduled to be discussed during a hearing on Wednesday.

Sanderson’s bill, which is available on the state’s website, does have its own stipulations. A child is required to have a longstanding relationship with the medical provider to be eligible for a prescription. Also, the child’s caregiver must supervise the allocation of the medicinal marijuana and permits it to be available at the child’s school, given it is in an acceptable form, such as CBD pills or vaporizer.

Also during Wednesday’s hearing, the Legislature’s health and human services committee will hear other updates regarding Maine’s current medical marijuana laws, such as the addition of opiate addiction to the qualifying conditions for a medical marijuana license. The current conditions that qualify include Alzheimer’s disease, PTSD, cancer, chronic pain, Amyotrophic Lateral Sclerosis, HIV, Parkinson’s disease and epilepsy, and more.

Maine is considered one of the more progressive states regarding marijuana. The state has had a medical marijuana program in place since 1999, and is one of eight states to have legalized recreational marijuana as well. Even though Maine is willing to prescribe children medical marijuana, Sanders wants kids to provide them with even more access. Many believe it can be dangerous to prescribe medical marijuana to children. Mainly the caution is due to the lack of research regarding the matter.

Continue reading
0 Comments

General Cannabis Corp. (CANN) Eyes California Market, Analysts Target, and Financial Review

General Cannabis Eyes California Market, Analysts Target, and Financial Review Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive report with no obligation on General Cannabis Corp. (CANN) a Denver-based company that offers a variety of products and services to companies in the cannabis sector. Its integrated solutions range from operational and compliance to security, marketing, and financing needs. The company operates through a number of subsidiaries including Chiefton Supply, Next Big Corp, Iron Protection all of which have stakes in the multi-billion cannabis industry.

CANN recently announced that it has signed a $955,000 two-year contract to manage a grow facility in California. This represents the largest single contract the company has undertaken since inception. The Company also plans to provide other services, including hardware and supply procurement, in addition to the initial contract terms.

Get more CANN updates, an analysts price target, and a financial review here:READ MORE.

Copy and paste into your browser may be required to view the report -http://bit.ly/2CJlLwa-CANN-Analyst.

This new contract for Next Big Crop, the business consulting and management arm of General Cannabis, represents the second major California-based project for the company. Iron Protection Group, the firm’s security division, opened an office near Sacramento earlier in 2017. Revenue from this new contract itself for the two-year contract period would be nearly equal to Next Big Crop’s trailing 12-month operations revenue stream for the period ending Sept. 30, 2017.

An estimate of the California cannabis market and how it impacts the overall market: READ MORE.

Continue reading
0 Comments

Marijuana Stocks Update: A Recipe For Success

Canada’s Marijuana Stocks Are Leading The Industry

The North American Marijuana industry is consistently growing like a weed and analyst believe this is only the beginning. ArcView has estimated that legal marijuana sales in North America have an annual growth rate of 26% through 2021. If this plays out, the industry will be valued around $22 billion by 2021, compared to 2016’s value of $6.9 billion. Massive growth is what continues to attract investors to one of the hottest industries of all time. However, this growth isn’t being led by the United States but rather Canada. Here’s why Canada is the number one driver of the industry.

Click Here For Full

A Recipe for Success & Longevity

We at Marijuana Stocks have been covering GT Biopharma, Inc OTCQB: (GTBP) (previously Oxis International) for almost 3 years. (GTBP) by far has been the longest running company we have provided coverage to & for GREAT REASON.

Click Here To See Why

Could Australia Be The World’s Next Largest Marijuana Exporter?

Australia is set to pass a new law, making it the world’s largest player in the medical marijuana industry. The law would permit Australian marijuana grow companies to export their products abroad, with not many restrictions. This puts the country down under in the position to rise to the top to become the world’s largest marijuana exporter.

Continue reading
0 Comments

Canada’s Marijuana Stocks Are Leading The Industry

The North American Marijuana industry is consistently growing like a weed and analyst believe this is only the beginning. ArcView has estimated that legal marijuana sales in North America have an annual growth rate of 26% through 2021. If this plays out, the industry will be valued around $22 billion by 2021, compared to 2016’s value of $6.9 billion. Massive growth is what continues to attract investors to one of the hottest industries of all time. However, this growth isn’t being led by the United States but rather Canada. Here’s why Canada is the number one driver of the industry.

First and foremost, Canada has a long-standing medical marijuana program. Since 2001, our neighbors to the north have legalized medical pot. According to Health Canada, which is the equivalent of the U.S. Department of Health and Human Services, the number of eligible medical patients is increasing by 10 percent each month. Medical marijuana, solely, has been enough for Canadian marijuana stocks to be profitable. For instance, MedReleaf (MEDFF) and Aphria (APHQF) have both profitable for the past two years just based on their medical marijuana sales.

Second, the political differences between the Canadian federal government and that of the United States make a large difference. Although, in the U.S twenty-nine states including the District of Columbia have legalized some form of marijuana, it remains illegal on the federal level. Attorney General Jeff Sessions is determined on reinstituting federal law and prosecuting medical marijuana businesses continues his war on marijuana.

On the other hand, recreational marijuana legalization was introduced by Prime Minister Justin Trudeau in April 2017, and Canada is set to become the second country in the world, behind Uruguay, to legalize recreational pot this July. The way Canada is approaching recreational taxation is nothing like how U.S. legal states tax marijuana products.

Canada recently presented a $0.78-per-gram tax on marijuana sales of up to $7.80 a gram, with a flat 10% tax on marijuana that is more expensive. This is a lower tax rate on marijuana than for alcohol. Trudeau believes that the only way the legal market will thrive is to be price competitive and drive black-market out of business. U.S. states are reliant for this additional tax revenue to assist with filling gaps in budgets. For instance, certain parts of California could pass along nearly a 45% tax to retail marijuana customers, which will only drive consumers into the hands of the black market.

Continue reading
0 Comments

Could Australia Be The World’s Next Largest Marijuana Exporter?

Australia is set to pass a new law, making it the world’s largest player in the medical marijuana industry. The law would permit Australian marijuana grow companies to export their products abroad, with not many restrictions. This puts the country down under in the position to rise to the top to become the world’s largest marijuana exporter.

On Thursday, the government announced that it will legalize the overseas export of medical marijuana. Shortly after this announcement, the stock prices of Australian marijuana grow companies skyrocketed, such as Cann Group, who saw their shares shoot up 35 percent. CEO of Cann Group, Peter Crock, said in an interview that the legalization of exports puts his company in position to generate revenue abroad in markets that cannot meet supply demands, like Germany.

According to a statement on the Minister for Health Greg Hunt’s website, the decision to legalize medical marijuana exports “will help both the domestic supply and Australian producers by strengthening the opportunities for domestic manufacturers. We’d like to be potentially the world’s number one supplier”.

Australian investment firms have also expressed enthusiasm regarding Prime Minister Malcom Turnbull government’s decision. The idea of a new floodgate opening from oversea investments into the country’s medical marijuana industry has them jumping for joy. Australia, like the U.S. states, has been able to make their own decisions regarding medical marijuana, yet, recreational use remains prohibited.

In 2016, medical access to marijuana became legal at the federal level. But, medical marijuana prescriptions are not all that popular in the country. According to Hunt, there are only a few hundred patients that receive marijuana products for treatment. But, why? Patients have reported difficulty in accessing legal medical pot and that doctors are refusing to prescribe it to them. Therefore, the country is seeking to legalize medical marijuana exports with the hope to jump-start the local industry and improve access for patients.

Continue reading
0 Comments

GT Biopharma Inc. (GTBP) Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004

 

GT Biopharma Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004 for Myasthenia Gravis

GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) today announced that it has completed dosing in its Phase 1 clinical trial for GTP-004, its promising treatment for the symptoms of myasthenia gravis. The results provide evidence that GTP-004 enables the safe and well-tolerated administration of doses of pyridostigmine.

GTP-004 combines pyridostigmine with ondansetron, designed to attenuate the gastro-intestinal (GI) side effects of pyridostigmine alone, providing the potential for a fully efficacious dose of pyridostigmine to be safely used. Based on the data, and discussions with key opinion leaders, GT Biopharma expects to be in a position to initiate a Phase 2 clinical trial in patients in the second half of 2018.

The objective of the Phase 1 clinical trial is to demonstrate that GI side effects are safely reduced with GTP-004. Five healthy volunteers were enrolled in the Phase 1 study. Following enrollment, subjects received single increasing oral doses of pyridostigmine (ranging from 30 to 120mg) administered once daily in the morning. Once subjects reached First Intolerable Dose (FID1) as defined by protocol criteria, upward dose escalation of pyridostigmine was discontinued and subjects were washed out for 2 to 7 days. Next, subjects that reached FID received daily increasing doses of pyridostigmine in combination with ondansetron.

Read Our Full (GTBP) Update Here

Three subjects (2 males, one female; aged 34 to 43) reached FID with pyridostigmine alone. The dose-limiting gastro-intestinal adverse event occurred at 60 mg for 2 subjects, and 90 mg for the third subject. When these three subjects received GTP-0004 (pyridostigmine with ondansetron), gastro-intestinal adverse events were abrogated, and all subjects tolerated doses as high as 120 mg, the maximum allowed dose allowed by the protocol.

Continue reading
0 Comments

Namaste Technologies Inc. (NXTTF) Announces Services Agreement With Cannamerx Cannabis Mercantile Exchange

Namaste Announces Services Agreement With Cannamerx Cannabis Mercantile ExchangeNamaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N)(M5BQ.F)(NXTTF) is pleased to announce that it has entered into a Services Agreement (the “Agreement”) with 3955 Trading Inc. (“Cannamerx”), Canada’s first online marketplace for the wholesale purchase of medical cannabis certified under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). Cannamerx is a fully automated, ACMPR-compliant forward auction trading platform for bulk cannabis and cannabis products in Canada. Developed in close collaboration with Canadian licensed producers, Cannamerx is designed to facilitate the trade of bulk cannabis and cannabis products between licensed producers throughout the country. Namaste believes that Cannamerx’s platform will offer strategic benefits to the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”), which is a late stage ACMPR applicant for a medical cannabis “sale-only” license. Through Cannmart, Namaste will create an online retail marketplace for medical cannabis that will offer the largest variety of products sourced from ACMPR licensed producers as well as international cultivators.

Terms of the Agreement:

All bids submitted over the platform are binding;Sale transactions are Ex Works;Cannamerx offers strong buyer protection to ensure products match descriptions;Cannamerx ensures that all ACMPR compliant;Cannamerx is strictly a business to business marketplace;Cannamerx does not charge sign-up or listing fees;Cannamerx does not charge any buyer commission;Bidding on Cannamerx is anonymous; andThe Agreement is non-exclusive to Cannmart.

Using the Cannamerx platform will enhance Namaste’s ability to efficiently source cannabis and cannabis products from small-scale licensed producers throughout Canada, creating a diverse product selection for Cannmart’s online marketplace customers.  While large licensed producers will continue to play a vital role in Namaste’s distribution, the Company believes that the Agreement will allow the Company to connect customers with the craft cannabis market, an important niche market that could experience significant growth similar to the craft beer and wine industries.

In addition to the announcement of the Agreement, Namaste would like to announce that Mr. Clifford Stark will be leaving Namaste’s board of directors in pursuit of a new business venture. Mr. Stark has provided Namaste with valuable advice and insight during his position as an active board member of Namaste’s team. The Company would like to thank Mr. Stark for his service and wishes him best of luck in his future endeavors.

Management Commentary“We are proud to welcome Namaste to Cannamerx,” said Dietwald Claus, CEO of 3955 Trading Inc., which owns and operates Cannamerx. “We developed Cannamerx to provide Canadian licensed producers with an effective, easy-to-use, ACMPR-compliant platform for the trade of wholesale cannabis and cannabis products in Canada. By bringing together licensed producers, processors, and retailers from across the country on a single trading platform, we anticipate that Cannamerx will play a critical role in growing a diversified and robust Canadian cannabis industry. Namaste’s decision to join Cannamerx is a strong vote of confidence in our technology and business model. We look forward to welcoming more participants over the coming months as Canada prepares to legalize recreational cannabis.”

Sean Dollinger, President and CEO of Namaste comments, “This Agreement represents a unique opportunity for both parties, as we look for new ways to increase the appeal of our online marketplace. Our relationship with Cannamerx is not intended to replace our existing supply channels, but rather to broaden the selection of quality cannabis products that we are able to provide to our customers. Namaste believes Cannamerx fits well with our purchasing strategy moving forward, and we anticipate Cannamerx playing a significant role in helping us access cannabis from smaller licensed producers to supply Canadian consumers with the most diverse selection in a cannabis space.”

Continue reading
0 Comments

Federal Law vs State Law

The Trump administration seems to be contradicting itself when stating that policies are best set by the states, rather than the federal government. This is not the case regarding marijuana laws, the states are not equipped to design the policy according to the Feds.

Last week, Attorney General Jeff Sessions publicly showed his opposition towards marijuana once again by rescinding an Obama-era memorandum that suppressed the prosecution of marijuana companies or activities if they deemed legal under the state’s laws. For instance, in the state of Maine, both medicinal and recreational marijuana are legalized. This means that businesses can cultivate and distribute marijuana if they followed certain regulations. This method allowed investors to make legal marijuana investments as well giving states a new avenue to generate revenue from sales.

Sessions’ memorandum creates enough uncertainty for legal marijuana businesses as well state regulators to slow down their efforts to create a legal market. The largest problem with the situation is that it does not address the original issue with marijuana policy. State and federal laws are conflicting with one another. Twenty-nine states have now passed laws legalizing some form of marijuana including eight states that have passed recreational marijuana laws. But, ultimately marijuana remains an illegal Schedule 1 narcotic under federal law.

President Obama’s method did not address the issue at hand, either. But, it did recognize that state laws have been changed through a democratic process. Voters incline approving legalization, yet all states do not allow its citizens to directly approve laws. Although flawed, it directed the nation to consider that Sessions’ memo, which permits prosecutors to use their judgment regarding marijuana laws in their district, does not really change much. U.S. attorneys are residents of the states in which they are employed and are aware of local political sentiments.

The possibility that a prosecutor, such as Maine’s U.S. Attorney Halsey Frank, will decide to establish a higher significance for federal crimes where there isn’t a conflict between state and federal laws. Efforts may focus on cross-state sales of opioids, illegal guns or human trafficking. There is also a possibility that advancements made regarding the marijuana reform go down the drain. Looks like we will just have to sit back and see what the future holds for this budding industry.

Continue reading
0 Comments

Top-Performing Marijuana Stocks Of The Fourth Quarter

The ever-growing marijuana industry continues to attract the attention of investors around the globe. From small-cap to large-cap, the marijuana industry is on fire. Last year was a great year for marijuana stocks. What’s even more exciting is what this year has in store for the industry. With the legalization of adult-use recreational marijuana in California and Canada this year, there will not be much in the way to stop these stocks from soaring. Here are a few marijuana stocks that thrived during Q4 of 2017 that we remain bullish on for 2018.

Aurora Cannabis (ACBFF) 371%

Aurora has taken the title as the largest publicly traded marijuana stock by market cap, recently surpassing a $5 billion market cap and really came out to shine during the Q4. Aurora has been working its acquisition of CanniMed Therapeutics’ (CMMDF) following an unsolicited bid of up to $425 million in November. Aurora has stated that combined company would have the ability produce 130,000 kilograms of dried marijuana annually. In early December, Aurora Cannabis aquired H2 Biopharma, adding a 48,000-square foot facility with a grow capability of 4,500 kilograms of marijuana annually when construction is complete. The outcome of the hostile bid, along the legalization of adult-use recreational marijuana in Canada, could push this marijuana stock even higher in 2018.

Canopy Growth Corp (TWMJF) 173%

Canopy Growth grew 173% during the fourth quarter. Probably one of the most noteworthy events during the quarter for Canopy was its deal with Constellation Brands (STZ), for a 9.9 percent stake into the marijuana company, to produce and retail marijuana infused beverages. In Canopy’s earnings release, it announced that 2.4 million square feet of growing capacity under construction and an option to acquire over another million square feet. With recreational legalization approaching, this marijuana stock is locked and loaded and ready to profit.

Continue reading
0 Comments

This Is What We’re Talking About!

This is exactly what we were talking about today! We at Marijuana Stocks have been covering GT Biopharma, Inc OTCQB: (GTBP) (previously Oxis International) for almost 3 years. (GTBP) by far has been the longest running company we have provided coverage to & for GREAT REASON. And right now we could be seeing it on the verge of major milestones…this includes a potential uplisting to the NASDAQ!

In its history Marijuana Stocks has NEVER covered a Marijuana Company that has up-listed from the OTC to the NASDAQ, this could all change with GT Biopharma, Inc OTCQB: (GTBP). We believe that we saw an early spark today with a strong 12% breakout and one of the company’s most active trading sessions within the last 8 months!

Does a NASDAQ Application make (GTBP) a company with great potential? Not by itself it doesn’t! You know what does? CLICK HERE

MARIJUANASTOCKS.com is owned by MAPH ENTERPRISES LLC., a Florida Corporation that has been compensated $150,000.00 by a GT Biopharma Inc. for a period beginning Jan 1, 2018 and ending Feb. 1, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer

The post This Is What We’re Talking About! appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Original link
0 Comments

Cannabis Science, Inc. (CBIS) Science Prepares for the Grand Opening of Its First Two Pre ICO Pharmacies

Cannabis Science Prepares for the Grand Opening of Its First Two Pre ICO Pharmacies in Prime, High Traffic Areas; State of the Art Tracking and Automation System is Being Installed NowCannabis Science, Inc. (OTC Pink: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company is preparing for the Grand Opening of its first two Pre ICO Pharmacies in California. These pharmacies will be managed through the use of a Pharmacy Automation and Inventory Tracking System.

“Cannabis Science’s Pharmacies are in prime, high traffic areas on Pico Boulevard in Los Angeles and on Ventura Boulevard in the San Fernando Valley. The Company has also been presented with an opportunity to purchase a potentially 60,000 sq. ft. building in Los Angeles, CA. This is where the Company can build its first Cannabis Science Medical Center, including full laboratory facilities, patient intake, and doctor and nurse clinics. We will look at the possible use of the Company’s rare U.S. Federal Government Cage Code Clearance to provide U.S. Federal Government approved Emergency Medical Services,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, CEO, and Co-founder.

“It is possible we will include our sister Company, Crown Baus Capital Corp (CBCA) in this purchase. Additional space will be leased to physician groups and other medical cannabinoid related health services and well-being providers. I am particularly excited about the Cannabis Science Medical Center, this was always one of our main goals,” stated Mr. Dabney. “This facility will serve as a hub for our activities. Not only will physicians be able to consult directly with patients at the Center, but the Company will also be able to coordinate and expand its global reach and research on cannabinoid-based drugs related to development initiatives through the Cannabis Science Global Research Consortium.

“Our Pharmacies are designed to be state of the art facilities and they will be beautiful. We will showcase the entire Cannabis Science product line, as well as additional products from select vendors that meet the high standards that we have set for our CBIS-branded products,” stated Mr. Dabney. “As part of the Company’s overall drug-development strategy, the Cannabis Science Pharmacies will provide our Company with an important retail sales channel and allow us to interact directly with those who will benefit from our medicines – our patients.”

These new acquisitions offer Cannabis Science a very strong foothold in the medical services industry. In addition, the Company is actively negotiating with its East Coast Associates in Washington, D.C and New York City to expand the CBIS-branded Pharmacies into those areas and expect to announce our progress in the coming months.

The Company launched the Cannabis Science Global Consortium in 2017. This Consortium provides a framework to cooperate and collaborate with stakeholders worldwide. “The Cannabis Science Global Consortium links universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside,” stated Dr. Allen Herman, Cannabis Science’s Chief Medical Officer.

Continue reading
0 Comments

A Recipe for Success & Longevity

We at Marijuana Stocks have been covering GT Biopharma, Inc OTCQB: (GTBP) (previously Oxis International) for almost 3 years. (GTBP) by far has been the longest running company we have provided coverage to & for GREAT REASON.

(GTBP) is constantly evolving, becoming the best version of itself. (GTBP) has consistently provided our members with double & even triple digit short term and long-term gains.

In its history Marijuana Stocks has NEVER covered a Marijuana Company that has up-listed from the OTC to the NASDAQ, this could all change with GT Biopharma, Inc OTCQB: (GTBP).

On December 18, 2017 GT Biopharma, Inc OTCQB: (GTBP) announced that it had filed its application for NASDAQ Capital Markets Listing. This press release shows that when Executive Chairman and former (GTBP) Chief Executive Officer Anthony J. Cataldo stated the company’s intention to up-list to NASDAQ on a shareholder conference call back on August 16, 2017 & on a post reverse shareholder conference call on October 2, 2017 he wasn’t joking. Take a moment to ask yourself this question… How many times have you heard of a marijuana penny stock company talk about a NASDAQ Up-Listing? How many times have they actual filed and took all needed steps to execute that up-listing? Our best guess is few and far between.

Does a NASDAQ Application make (GTBP) a company with great potential? Not by itself it doesn’t! You know what does?MANAGEMENT:Kathleen Clarence-Smith, M.D., PH.D. (Chief Executive Officer & Director) – Dr. Clarence-Smith founded GTP in 2015. Prior to founding GTP, she co-founded Chase Pharmaceuticals Corporation in Washington D.C. and served as Chairman of the company’s Board from 2008 to 2014. Chase Pharmaceuticals was acquired by Allergan, PLC (AGN) in 2016 for $125 million together with potential addition payments of $875 million based upon regulatory and commercial milestones. Dr. Clarence-Smith also held executive management positions with Sanofi, Roche, Otsuka Pharmaceutical and Prestwick Scientific Capital. She is co-founder and a managing member of KM Pharmaceutical Consulting in Washington, D.C.Shawn Cross (President & Chief Operating Officer) – Mr. Cross was a Managing Director, and senior calling officer focused on the biopharmaceutical industry, in Healthcare Investment Banking at Deutsche Bank Securities Inc. (NYSE:DB) from November 2015 to October 2017. He was a Managing Director in the Wells Fargo Securities, LLC. (NYSE:WF) Healthcare Group from December 2010 to November 2015. Mr. Cross began his 20-year investment banking career at Alex. Brown & Sons Inc. and has lived and worked in the major financial centers of London, New York City and San Francisco. He received his bachelor of science degree from the University of California, Los Angeles and his Master’s in Business Administration from Columbia Business School with honors and a concentration in Finance.Raymond Urbanski, M.D., PH.D. (Chief Medical Officer) – Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab. In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.Anthony J. Cataldo (Executive Chairman) – Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of 2014, where he changed the Company’s profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., (IOVA). Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.Steven Weldon (Chief Financial Officer & Director) - Steven Weldon join GT Biopharma, Inc. as member of the Board of Directors in September 2014 and as our President and Chief Financial Officer in November 2014. Previously, Mr. Weldon was the Chief Financial Officer and a member of the board of directors of GB Sciences, Inc. from September 2005 to November 2014. Mr. Weldon also served as chief executive officer of Growblox Sciences from December 29, 2009, through May 2, 2011, and from April 18, 2012, through March 13, 2014. For several years, he taught accounting and tax courses to undergraduate students at Florida Southern College. He received his Bachelor of Science degree and his Master’s in Business Administration from Florida Southern College. Mr. Weldon is a Certified Public Accountant licensed to practice in the State of Florida.REAL CORPORATE DEVELOPMENTFrom their NASDAQ Up-Listing filing, Public Drug Data Presentations, Approved FDA IND Transfer of its First TriKE (OXS-3550) to the start of its Manufacturing of its “Non-Opioid” Pain-Brake Drug and so much more, GT Biopharma, Inc OTCQB: (GTBP) has consistently pushed the needle forward.

What we are outlining here is in our opinion OUR BEST EXAMPLE of a Recipe for longevity and success. It is our opinion given all that (GTBP) has shown that this is not a “fly by night” company. It is our opinion that this company will stand the test of time & continue to provide value to its shareholders.

Continue reading
0 Comments

Aphria Inc. (APHQF) secures additional 120,000 kgs of expected annual cannabis production for January 2019(1)

Aphria secures additional 120,000 kgs of expected annual cannabis production for January 2019(1)Aphria Inc. (“Aphria” or the “Company“) (TSX: APH and US OTC: APHQF) today announced that it has entered a strategic relationship (“GrowCo“) with Double Diamond Farms (“Double Diamond“), a local greenhouse grower, to provide an additional 120,000 kgs of annual cannabis production.  The deal accelerates Aphria’s capacity increase by over a year versus building out its existing 100-acre site.  Combined with Aphria’s existing expected cannabis production of 100,000 kgs, Aphria will have, what it believes to be, the largest fully funded production capabilities in the industry in 2019.  Aphria anticipates that all 220,000 kgs of expected annual cannabis production will be available for sale in January 2019 , pending Health Canada approvals.

“Since the Aphria journey began in early 2014, a key pillar to the Aphria success story has been our unwavering commitment to “powered by the sun”, and nowhere is that more effective than in Leamington, Ontario , where average daily sunlight hours, intensity of optimum lighting and moderate climate provides for ideal greenhouse growing,” said Vic Neufeld , Chief Executive Officer.  “Building on our Leamington advantages, I am very excited to announce that Aphria has entered into another acquisition of Dutch greenhouse campus in the Leamington area. Partnering with Double Diamond, a major local greenhouse grower, Aphria will have access to almost 32.0 acres (just less than 1,400,000 square feet of greenhouse) plus 72,000 of infrastructure to service not only the almost 32 acres, but a future build of another 32 acres.  Double Diamond is an industry-recognized leader in growing various produce using the greenhouse technology advancements, and brings solid talent and a labour pool necessary to support the annual incremental capacity of over 120,000 kgs.”

Owners of Double Diamond Chris and Benji Mastronardi are pleased to have the opportunity to pair Double Diamond Farms’ growing experience with Aphria’s growing experience and sales expertise.  “It made our decision to partner with Aphria an easy choice,” said Chris Mastronardi , Chief Executive Officer of Double Diamond Farms.  “The staff at Double Diamond Farms are excited about this new challenge and to be able participate in the burgeoning medical and adult recreational use cannabis markets,” said Benji Mastronardi , President and COO of Double Diamond Farms.

Double Diamond, a 49% partner in GrowCo, will supply the land, new state of the art, Dutch style greenhouses, existing infrastructure and employees for the venture.  Aphria, holding a controlling 51% interest in GrowCo, will supply its Standard Operating Procedures, quality oversight and will apply for a second Health Canada cultivation license for the site.  The 100-acre site is located on Highway 77 in Leamington, Ontario , has never had another crop planted inside of it and abuts Aphria’s existing second campus, comprised of another 100-acre site.

GrowCo is expected to require funding of $80 – $100 million , including acquiring the property based on appraised value, plus the cost of retrofits, power co-generation facilities and other cannabis specific investments.  GrowCo will initially be funded by a $10 million investment by each of Aphria and Double Diamond.  Additional funding will be secured through traditional term debt from commercial lenders.  Any shortfall in funding, will be advanced by Aphria as a loan.

We Have a Good Thing Growing.

Continue reading
0 Comments

What States Will Go Legal Next In 2018?

Almost a dozen states are poised to consider marijuana legalization this year, with more possibly jump on board as legislative sessions continue, making 2018 a potentially crucial year in the burgeoning cannabis movement. Some states are even planning to take unprecedented legislative steps to make marijuana—either recreational or medical-legal and more easily accessible.

“With over 60 percent of Americans now supporting the full legalization of marijuana for adults, the momentum behind marijuana law reform will not only continue but increase as we head into 2018,” Erik Altieri, executive director for the National Organization for the Reform of Marijuana Laws,

Vermont: Recreational Marijuana

Vermont legislators are awaiting a landmark move for marijuana advocates in early 2018. The state will have the first governor and Legislature to legalize recreational weed, as opposed to a citizen-driven ballot initiative.

The Democrat-controlled Legislature green lit recreational marijuana back in May 2017, even though Republican Governor Phil Scott vetoed the Bill. He instead ordered the creation of a bipartisan commission to study public health issues surrounding the proposed marijuana legalization, such as how to measure driving impairment and the impact on existing substance abuse problems like the opioid crisis. In December 2017, Scott told Vermont Public Radio that he was “comfortable” approving a recreational marijuana law in 2018.

Continue reading
0 Comments

Are These Marijuana Stocks Due For A Bounce?

On Thursday, Attorney General Jeff Sessions once again showcased his opposition towards marijuana by rescinding an Obama-era memorandum to alleviate the enforcement of federal marijuana laws in the states that have legalized marijuana. This move had repercussions for the entire North American industry, triggering a sharp sell-off of marijuana stocks.

One of the marijuana stocks that took the largest blow was Aphria Inc. (APHQF), a Canadian marijuana company investing in medical marijuana in Florida. Aphria’s (APHQF) shares closed the day down 13%. Insys Therapeutics (INSY) a biotech company with cannabinoid drugs in its pipeline fell over 26%, while companies that do not even operate in the United States took hits, such as Canopy Growth (TWMJF) dropping 10%.

Twenty-nine states have now passed laws legalizing some form of marijuana including eight states that have passed recreational marijuana laws. The largest of those states, California, commenced its recreational marijuana market on Jan. 1, a market that is forecast to become the largest in the world. Even though most U.S. states are accepting of marijuana, it remains illegal at the federal level and its classified by the Drug Enforcement Agency (DEA) as Schedule 1 narcotic.

In 2013, a memorandum from then Deputy Attorney General James Cole moved the focus away from companies and individuals legally participating in pro-marijuana states towards only prosecuting the behaviors that remained illegal. Cole’s memorandum did not abolish federal authority to prosecute marijuana violators in pro-marijuana states, but it made it transparent that the enforcement should primarily be up to the state and local authorities and not the U.S. government. Sessions’ decision to rescind Cole’s memo doesn’t considerably change all that much. The federal government always retained the ability to get involved under Cole’s memo in the pro-marijuana states, it just didn’t.

We can only wait to see whether any pro-marijuana state attorney general will suppress marijuana activity following Sessions move. For marijuana advocates and investors, the optimism of a more supportive federal government remains unlikely under the Trump administration.

Continue reading
0 Comments

Aurora Cannabis Inc. (ACBFF) Appoints Cam Battley Chief Corporate Officer

Aurora Cannabis Appoints Cam Battley Chief Corporate OfficerAurora Cannabis Inc. (the “Company” or “Aurora”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) is pleased to announce that Cam Battley has been promoted to Chief Corporate Officer (CCO).

Mr. Battley joined the Company in March, 2016, and previously held the positions of Executive Vice President and Senior Vice President with Aurora. In his new role, he will be the lead external-facing executive of the Company, responsible for establishing and managing relationships with shareholders, industry analysts, news media, securities regulators, licensing bodies, governments, other companies and organizations operating in the cannabis sector, and other external stakeholders. He will also chair the Executive Committee, work closely with the Company’s legal counsel, act as liaison with the Board of Directors, and ensure organizational alignment with regard to strategic partnerships and corporate development across all of the Company’s operations, domestic and international.

Mr. Battley, who has more than 15 years of experience in the global biopharmaceutical industry, is a member of the Board of Directors of Cannabis Canada, the trade association for Health Canada Licensed Producers. He also currently serves as a member of the Board of the patient advocacy group Campaigning for Cancer ( South Africa ), and of Micron Waste Technologies Inc. (CSE:MWM), a Vancouver -based developer of advanced digesters for organic waste materials.

“Cam’s experience, judgment, energy, and passion for this business have been key drivers in Aurora’s rapid emergence as a leader in the global cannabis industry,” said Terry Booth , CEO. “I am extremely proud of the quality, competence and consistent execution of our executive team, and am delighted that Cam will be playing a central role with Aurora as we accelerate our domestic and international expansion.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta , known as “Aurora Mountain”, a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island, and is currently constructing an 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.

Continue reading
0 Comments